Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Vivos Therapeutics (VVOS) Loans and Notes Receivables (2019 - 2021)

Vivos Therapeutics' Loans and Notes Receivables history spans 3 years, with the latest figure at $61864.0 for Q3 2021.

  • Quarterly results put Loans and Notes Receivables at $61864.0 for Q3 2021, changed N/A from a year ago — trailing twelve months through Sep 2021 was $61864.0 (changed N/A YoY), and the annual figure for FY2020 was $84000.0, down 0.82%.
  • Loans and Notes Receivables for Q3 2021 was $61864.0 at Vivos Therapeutics, up from $56732.0 in the prior quarter.
  • In the past five years, Loans and Notes Receivables ranged from a high of $84696.0 in Q4 2019 to a low of $56732.0 in Q2 2021.
  • The 3-year median for Loans and Notes Receivables is $84000.0 (2020), against an average of $74397.6.
  • Peak annual rise in Loans and Notes Receivables hit 0.82% in 2020, while the deepest fall reached 0.82% in 2020.
  • Year by year, Loans and Notes Receivables stood at $84696.0 in 2019, then fell by 0.82% to $84000.0 in 2020, then dropped by 26.35% to $61864.0 in 2021.
  • According to Business Quant data, Loans and Notes Receivables over the past three periods came in at $61864.0, $56732.0, and $84696.0 for Q3 2021, Q2 2021, and Q1 2021 respectively.